|
Pegylated Liposomal Doxorubicin Hydrochloride Clinical Trials
5 actively recruiting trials across 4 locations
▲ +1 trial since June 2026
Also known as: ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen +16 more
Pipeline
Phase 1: 1Phase 2: 4
Top Sponsors
- National Cancer Institute (NCI)2
- University of Washington1
- Roswell Park Cancer Institute1
- Hebei Medical University Fourth Hospital1
Indications
- Cancer5
- Breast Cancer3
- Metastatic Triple-Negative Breast Carcinoma2
- Anatomic Stage IV Breast Cancer AJCC v82
- Locally Advanced Unresectable Triple-Negative Breast Carcinoma1
Other1 trial
Los Angeles, California1 trial
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Los Angeles General Medical Center
Phase 1
Bethesda, Maryland1 trial
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute Developmental Therapeutics Clinic
Phase 2
Buffalo, New York1 trial
Seattle, Washington1 trial
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Fred Hutch/University of Washington Cancer Consortium
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.